Recent Analysts’ Ratings Updates for BioCryst Pharmaceuticals (BCRX)

Share on StockTwits

Several analysts have recently updated their ratings and price targets for BioCryst Pharmaceuticals (NASDAQ: BCRX):

  • 4/15/2019 – BioCryst Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
  • 4/9/2019 – BioCryst Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
  • 4/3/2019 – BioCryst Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
  • 4/3/2019 – BioCryst Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 4/2/2019 – BioCryst Pharmaceuticals had its price target raised by analysts at JMP Securities from $16.00 to $18.00. They now have a “market outperform” rating on the stock.
  • 4/2/2019 – BioCryst Pharmaceuticals had its price target raised by analysts at Barclays PLC from $6.00 to $8.00. They now have an “equal weight” rating on the stock.
  • 3/26/2019 – BioCryst Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
  • 3/19/2019 – BioCryst Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 3/18/2019 – BioCryst Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
  • 3/11/2019 – BioCryst Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
  • 2/28/2019 – BioCryst Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

Shares of NASDAQ BCRX traded down $0.36 during midday trading on Wednesday, hitting $7.98. The stock had a trading volume of 4,959 shares, compared to its average volume of 847,401. The firm has a market capitalization of $895.21 million, a P/E ratio of -8.14 and a beta of 1.80. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.76 and a 1-year high of $9.95. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.65 and a quick ratio of 1.62.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, March 4th. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. The business had revenue of $2.73 million for the quarter, compared to the consensus estimate of $2.39 million. BioCryst Pharmaceuticals had a negative return on equity of 175.83% and a negative net margin of 490.25%. On average, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -1.19 EPS for the current fiscal year.

In related news, CFO Thomas R. Staab II sold 5,000 shares of the firm’s stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $9.85, for a total transaction of $49,250.00. Following the sale, the chief financial officer now directly owns 133,426 shares in the company, valued at approximately $1,314,246.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Lynne Powell sold 12,000 shares of the firm’s stock in a transaction dated Monday, January 28th. The shares were sold at an average price of $9.75, for a total value of $117,000.00. Following the sale, the vice president now owns 6,000 shares in the company, valued at $58,500. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,500 shares of company stock worth $308,725. Company insiders own 4.50% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. RA Capital Management LLC increased its holdings in BioCryst Pharmaceuticals by 15.4% during the 4th quarter. RA Capital Management LLC now owns 10,660,349 shares of the biotechnology company’s stock worth $86,029,000 after purchasing an additional 1,425,657 shares during the last quarter. BlackRock Inc. increased its holdings in BioCryst Pharmaceuticals by 0.9% during the 4th quarter. BlackRock Inc. now owns 8,849,427 shares of the biotechnology company’s stock worth $71,413,000 after purchasing an additional 79,571 shares during the last quarter. Vanguard Group Inc increased its holdings in BioCryst Pharmaceuticals by 9.2% during the 3rd quarter. Vanguard Group Inc now owns 5,798,229 shares of the biotechnology company’s stock worth $44,240,000 after purchasing an additional 490,319 shares during the last quarter. Vanguard Group Inc. increased its holdings in BioCryst Pharmaceuticals by 9.2% during the 3rd quarter. Vanguard Group Inc. now owns 5,798,229 shares of the biotechnology company’s stock worth $44,240,000 after purchasing an additional 490,319 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in BioCryst Pharmaceuticals by 9.7% during the 4th quarter. Geode Capital Management LLC now owns 1,227,763 shares of the biotechnology company’s stock worth $9,908,000 after purchasing an additional 108,785 shares during the last quarter. Institutional investors own 91.90% of the company’s stock.

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Read More: Compound Interest

Receive News & Ratings for BioCryst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.